A Phase 1, Single Center, Open Label Study to Evaluate the Metabolism and Excretion of [14C] CC 92480 in Healthy Male Subjects
Latest Information Update: 30 Nov 2021
Price :
$35 *
At a glance
- Drugs Mezigdomide (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 17 Nov 2021 Status changed from not yet recruiting to completed.
- 25 Sep 2020 New trial record